ALPHARETTA, Ga.--SANUWAVE Health, Inc., (OTC BB: SNWV) (www.sanuwave.com) an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, has appointed Maria Siemionow, M.D., Ph.D., Director of Plastic Surgery Research, and Head of Microsurgery Training in the Plastic Surgery Department of Cleveland Clinic, to its Scientific Advisory Board.
“It is a great honor to have Dr. Siemionow, a well-regarded expert in plastic and reconstructive surgery, join our Scientific Advisory Board”
“It is a great honor to have Dr. Siemionow, a well-regarded expert in plastic and reconstructive surgery, join our Scientific Advisory Board,” said Christopher M. Cashman, President and CEO of SANUWAVE. ”Dr. Siemionow has made significant contributions to our scientific research for the past three years. As a member of our Scientific Advisory Board, her continued contributions will be pivotal to the Company as we prepare to advance our pipeline through clinical development and commercialization.”
Dr. Siemionow, who gained worldwide acclaim in December 2008 when she successfully performed the first human facial transplant in the United States, is the first U.S. physician to receive Institutional Review Board approval for facial transplantation surgery. She received her medical degree from the Poznan Medical Academy in Poland, where she completed her residency in orthopedics and earned her Ph.D. in microsurgery. She recently received an honorary academic appointment as Professor of Surgery at the Medical University in Poznan. Dr. Siemionow is the recipient of several awards, including the James Barrett Brown Award for best publication in plastic surgery journals, American Association of Plastic Surgeons, 2004 and 2007.
Dr. Siemionow and her team at Cleveland Clinic completed the early pre-clinical work during the development of dermaPACE™, SANUWAVE’s lead product, that is currently in an Investigational Device Exemption (“IDE”) clinical trial evaluating Pulsed Acoustic Cellular [removed]PACE™) technology and the safety and efficacy of dermaPACE™ for its first indication, the healing of diabetic foot ulcers. SANUWAVE intends to apply its proprietary technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Dr. Siemionow, whose work was instrumental in developing dermaPACE™’s mechanism of action details, also conducted research in microcirculation and inflammatory reaction using PACE™ technology.
“Our research has demonstrated the potential this technology has in plastic surgery and reconstructive surgery indications,” said Dr. Maria Siemionow. “The direct effects on microcirculation, leukocyte activity and tissue regeneration through induced pro-angiogenic growth factor production, improved microcirculation and positive inflammatory responses create a favorable wound healing environment that is capable of long-term tissue sustainability. As a member of the Scientific Advisory Board, I look forward to undertaking a more active role in helping management assess the technology and its emerging indications.”
Mr. Cashman concluded, “Dr. Siemionow’s participation on our Scientific Advisory Board is indicative of our ongoing efforts to have the most talented clinicians and researchers involved in SANUWAVE’s efforts to research, develop and commercialize our products. Her work on wound care and ischemia reperfusion has been instrumental in guiding the Company in our efforts, and we look forward to her continued contributions as an integral member of our Scientific Advisory Board.”
Dr. Siemionow is a paid consultant for SANUWAVE.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. ( www.sanuwave.com) is an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area for the repair and regeneration of tissue, musculoskeletal and vascular structures. SANUWAVE’s portfolio of products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration. SANUWAVE intends to apply its Pulsed Acoustic Cellular [removed]PACE™) technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE™, is CE marked for treatment of the skin and subcutaneous soft tissue and is currently involved in an FDA-approved Investigational Device Exemption trial in the U.S. for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide and believes it has already demonstrated that this technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved Ossatron® device and in the stimulation of bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its Ossatron® and Evotron® devices in Europe. For more information about the dermaPACE™ trial, please visit www.dermapace.com.
Safe Harbor Statement
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.